1 citations
,
January 2024 in “NPJ breast cancer” Experts agree on how to manage sugar levels and skin reactions in patients taking the cancer drug alpelisib.
10 citations
,
July 2022 in “Journal of Medicinal Chemistry” Adding a second method to PROTACs could improve cancer treatment.
November 2023 in “SKIN The Journal of Cutaneous Medicine” March 2026 in “Journal of Clinical Oncology” Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.
12 citations
,
September 2015 in “Drug Design Development and Therapy” AD198 is more effective than doxorubicin in stopping certain dog cancer cells.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Most patients with alopecia areata see significant hair regrowth within 93 days of starting ritlecitinib treatment.
1 citations
,
August 2022 in “Journal of Dermatology and Dermatologic Surgery” A patient developed nerve problems as a side effect of a hair loss treatment called tofacitinib.
5 citations
,
October 2024 in “Reumatismo” Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.
April 2018 in “Journal of Investigative Dermatology” CREB, a protein that can promote cancer traits, is controlled by β-catenin in skin cancer cells.
14 citations
,
August 2007 in “Bioorganic & Medicinal Chemistry Letters” The compound (1R,2S)-4-(2-Cyano-cyclohexyl-oxy)-2-trifluoromethyl-benzonitrile can stimulate hair growth and reduce oil production when applied topically.
2 citations
,
January 2025 in “Сибирский научный медицинский журнал” TS-13 effectively stops tumor growth and reduces chemotherapy side effects.
13 citations
,
June 2008 in “International Journal of Dermatology” Sorafenib can cause a unique skin reaction.
3 citations
,
April 2020 in “PubMed” Combining DEB-BACE with chemotherapy is more effective and has fewer side effects than chemotherapy alone for treating unresectable lung squamous cell carcinoma.
June 2026 in “Strathprints: The University of Strathclyde institutional repository (University of Strathclyde)” The study investigates NF-κB signalling in CYLD cutaneous syndrome (CCS) tumours to identify potential drug targets. Researchers used transcriptomics, proteomics, and single-cell RNA sequencing on patient-derived CCS tumour cells, revealing evidence of non-canonical NF-κB signalling with increased p100 to p52 processing and RelB protein expression. IκB kinase alpha (IKKα) was identified as a candidate target, and a novel IKKα inhibitor (SU1644) was tested on CCS tumour spheroid cultures, showing reduced tumour viability. The findings support the potential use of topical IKKα inhibitors as a preventive treatment for CCS.
2 citations
,
May 2017 in “Journal of the American Academy of Dermatology” Tofacitinib helped a 19-year-old regrow hair after other treatments failed.
1 citations
,
July 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.
June 2024 in “Journal of Clinical Oncology” The combination of TACE and Donafenib is effective and tolerable for treating unresectable liver cancer.
November 2025 in “Journal of Investigative Dermatology”
21 citations
,
February 2013 in “Clinics in Dermatology” New treatments for advanced skin cancer are improving patient outcomes, but drug resistance and finding the right treatment combinations are still big challenges.
7 citations
,
September 2024 in “Journal of Comparative Effectiveness Research” Palbociclib generally maintains or improves quality of life in advanced breast cancer patients.
10 citations
,
September 2024 in “Life” Abrocitinib shows promise for treating various skin conditions beyond atopic dermatitis.
1 citations
,
March 2023 in “Anais Brasileiros de Dermatologia”
June 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
2 citations
,
December 2013 in “Cancer research” Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.
5 citations
,
August 2024 in “Frontiers in Immunology” Upadacitinib effectively treats psoriasiform eczema and some related conditions.
June 2024 in “International Journal of Dermatology” Upadacitinib may effectively treat resistant lichen planopilaris.
August 2023 in “Frontiers in Oncology” New drugs and therapies targeting specific pathways show promise in treating advanced prostate cancer.
69 citations
,
February 2021 in “PLoS Computational Biology” Securinine and ajmaline may effectively treat liver cancer, with securinine being less toxic to normal cells.
1 citations
,
September 2022 in “International Journal of Trichology” Tofacitinib can be effective in treating hair loss caused by alopecia areata.
April 2025 in “The Journal of Dermatology” Janus kinase inhibitors may help treat cutaneous T-cell lymphoma, but more research is needed.